Abbott to sell i-STAT BNP test to diagnose congestive heart failure

By Elaine Rigoli

Tampa, Fla., July 26 - Abbott has received 510(k) clearance from the Food and Drug Administration to market its i-STAT BNP cartridge, a new point-of-care diagnostic test used to assess the level of brain naturietic peptide (BNP) in patients in emergency rooms, heart-failure clinics and observation units, laboratories and other critical-care settings.

BNP is a protein secreted into the bloodstream by heart tissue during congestive heart failure, a disease in which the heart loses its ability to adequately pump blood throughout the body, resulting in a build-up of fluid pressure inside the heart.

Abbott is a global health care company located in Abbott Park, Ill.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.